Thromb Haemost 1976; 35(02): 403-414
DOI: 10.1055/s-0038-1647935
Original Article
Schattauer GmbH

The Effects of Therapy with Oestriol Succinate and Ethinyl Oestradiol on the Haemostatic Mechanism in Post-Menopausal Women

Terence Davies
1   University Department of Medicine, The General Infirmary, Leeds LSI. 3EX.
,
Gillian Fieldhouse
1   University Department of Medicine, The General Infirmary, Leeds LSI. 3EX.
,
George P. McNicol
1   University Department of Medicine, The General Infirmary, Leeds LSI. 3EX.
› Author Affiliations
Further Information

Publication History

Received 11 August 1975

Accepted 11 September 1975

Publication Date:
02 July 2018 (online)

Summary

The effects on the haemostatic mechanism of oestrogen therapy, given to prevent bone loss in post-menopausal women, have been investigated. Oestriol succinate was given orally to 10 women at a level of 2 mg/day for 1 month and for a further 3 months with incremental increase of 2 mg each month. 6 of the 10 women were subsequently treated with 25 μg/day orally of ethinyl oestradiol. Oestriol succinate therapy resulted in a small increase in the level of factor VII, a decrease in factor VIII concentration and increased sensitivity of platelets to aggregating agents. Ethinyl oestradiol treatment resulted in much more widespread changes with marked increases in coagulation factors VII, VIII, IX and X, decreased levels of antithrombin and dramatic increases in circulating plasminogen levels and euglobulin lysis activity. The data suggested that the nature of oestrogens employed therapeutically is important in determining the qualitative and quantitative effect of oestrogen therapy on components of the haemostatic mechanism.

 
  • References

  • 1 Aitken M, Hart D. M, Lindsay R. 1973; Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. British Medical Journal 3: 515.
  • 2 Alkjaersig N, Fletcher A. P, Sherry S. 1969; The mechanism of clot dissolution by plasmin. Journal of Clinical Investigation 38: 1086.
  • 3 Ambrus J. L, Niswander K. R, Courey W. G, Wamsteker E. F, Mink I. 1969; Progestational agents and blood coagulation. American Journal of Obstetrics and Gynaecology 103: 994.
  • 4 Amris C. J, Starup J. 1967; The coagulation mechanism in oral contraception. Acta Obstetricia et Gynaecologica Scandinavica 46: 78.
  • 5 Biggs R. 1972. Human blood coagulation, haemostasis and thrombosis. Blackwell Scientific Publications; Oxford: 651.
  • 6 Blix S. 1961; Studies on the fibrinolytic system in the euglobulin fraction of human plasma. Scandinavian Journal of Clinical and Laboratory Investigation 13 (58) p. 3.
  • 7 Bonnar J, McNicol G. P, Douglas A. S. 1969; Fibrinolytic enzyme system and pregnancy. British Medical Journal 3: 287.
  • 8 Born G. V. R, Cross M. J. 1963; The aggregation of blood platelets. Journal of Physiology (London) 168: 178.
  • 9 Bowie W. E. J, Owen C. A, Thompson J. H, Didisheim P. 1969; Platelet adhesiveness in von Willebrand’s disease. American Journal of Clinical Pathology 52: 69.
  • 10 Brakman P, Sobrero A. J, Astrup T. 1970; Effects of different systemic contraceptives on blood fibrinolysis. American Journal of Obstetrics and Gynaecology 106: 187.
  • 11 Breckendridge R. T, Ratnoff O. D. 1962; Studies on the nature of the circulating anticoagulant directed against anti-haemophilic factors. Blood 20: 137.
  • 12 Daniel D. G, Bloom A. L, Giddings J. C, Campbell H, Turnbull A. C. 1968; Increased factor IX in puerperium during administration of diethylstilboestrol. British Medical Journal 1: 801.
  • 13 Davies T, Lederer D. A, Davies A. J, McNicol G. P. 1974; The effect of aspirin on exercise-induced changes in platelet function and blood coagulation. Thrombosis Research 5: 69.
  • 14 Donayre J, Pincus G. 1965; Effects of Enovid on blood clotting factors. Metabolism 14: 418.
  • 15 Farbiszewski R, Kurowska T. 1970; Platelet adhesiveness, aggregation and fibrinolysis after the oral administration of the contraceptive ‘Lyndiol’. Thrombosis et Diathesis Haemorrhagica 24: 304.
  • 16 Gallagher J. C, Nordin B. E. C. 1973 Oestrogens and calcium metabolism; in Van Keep and Lauritzen Ageing and Oestrogens. Frontiers Hormone Research. 2 98 (Karger, Basel).
  • 17 Gallagher J. C, Nordin B. E. C. 1974; Personal communication Hakim C. A, Elder M. G, Hawkins D. F. (1969): Plasma factor IX levels in patients given hexoestrol or stilboestrol to suppress lactation. British Medical Journal 4: 82.
  • 18 Hedlin A. M. 1975; The effect of oral contraceptive estrogen on blood coagulation and fibrinolysis. Thrombosis et Diathesis Haemorrhagica 33: 370.
  • 19 Holmsen H, Day H. J, Storm E. 1969; Adenine nucleotic metobolism of blood platelets VI. Subcellular localisation of nucleotide pools with different function in the blood platelet release reaction. Biochemica Biophysica Acta 186: 254.
  • 20 Houghie C, Rutherford R. N, Banks A. L, Coburn W. A. 1965; Effect of a progrestin-estrogen oral contraceptive on blood clotting factors. Metabolism 14: 411.
  • 21 Howie P. W, Mallinson A. C, Prentice C. R. M, Horne C. H. W, McNicol G. P. 1970; Effect of combined oestrogen-progestogen oral contraceptives, oestrogen, and progestogen on antiplasmin and antithrombin activity. Lancet II: 1329.
  • 22 Howie P. W, Prentice C. R. M, McNicol G. P. 1973; A method of antithrombin estimation using plasma defibrinated with ancrod. British Journal of Haematology 25: 101.
  • 23 Langdell R. D, Wagner R. H, Brinkhouse K. M, Hill C. W. C. 1953; Effect of antihaemophilic factor on one-stage clotting tests. Journal of Laboratory and Clinical Medicine 41: 637.
  • 24 McNicol G. P, Gale S. B, Douglas A. S. 1963; In vitro and in vivo studies of a preparation of urokinase. British Medical Journal 1: 909.
  • 25 Medical Research Council. 1967; Risk of thromboembolic disease in women taking oral contraceptives: A preliminary communication by a sub-committee. British Medical Journal 2: 355.
  • 26 Mielke C. H, Kaneshiro M. M, Maher I. A, Weiner J. M, Rapaport S. I. 1969; The standardised normal Ivy bleeding time and its prolongation by aspirin. Blood 34: 204.
  • 27 Miller S. P, Lee S. L, Ritz N. 1965; Progestin-estrogen (SC 11,800) therapy and the haemostatic mechanism — a controlled study. Metabolism 14: 398.
  • 28 Nilsson I. M, Kullander S. 1967; Coagulation and fibrinolytic studies during use of gestagens. Acta Obstétrica et Gynecologica Scandinavica 46: 78.
  • 29 Pechet L, Alexander B. 1961; Increased clotting factors in pregnancy. New England Journal of Medicine 265: 1093.
  • 30 Poller L. 1973. Oral contraception, blood coagulation and platelets. In: Poller L. (ed.) Recent Advances in blood coagulation. p. 181 Churchill; London:
  • 31 Poller L, Thomson J. M. 1966; Clotting factors during oral contraception: further report. British Medical Journal 2: 23.
  • 32 Quick A, Stanley-Brown M, Bancroft F. W. 1935; A study of the coagulation defect in haemophilia and in jaundice. American Journal of Medical Science 190: 501.
  • 33 Ratnoff O. D, Colopy J. E, Pritchard J. A. 1954; The blood clotting mechanism during normal parturition. Journal of Laboratory and Clinical Medicine 44: 408.
  • 34 Ratnoff O. D, Menzte C. 1951; A new method for determination of fibrinogen in small samples of plasma. Journal of Laboratory and Clinical Medicine 37: 316.
  • 35 Talbert L. M, Langdell R. D. 1964; Normal values of certain factors in the blood clotting mechanism in pregnancy. American Journal of Obstetrics and Gynecology 90: 44.
  • 36 Vessey M. P, Doll R. 1969; Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. British Medical Journal 2: 651.
  • 37 von Kaulla E, von Kaulla K. N. 1970; Oral contraceptives and low antithrombin in activity. Lancet I: 36.
  • 38 Ygge J, Brody S, Korsan-Bengtsen K, Nilsson L. 1969; Changes in blood coagulation and fibrinolysis in women receiving oral contraceptives. American Journal of Obstetrics and Gynecology 104: 87.